NLRP3 and osteoporosis: MSC-EVs ameliorate osteoporosis by inhibiting NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome activation, as the negative regulation of NLRP3 inflammasome activation inhibits IL-1β and IL-18 secretion in osteoclasts, promoting recovery from bone loss [83, 84].